Stockreport

Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review [Yahoo! Finance]

Theratechnologies Inc. - Common Shares  (THTX) 
PDF F8 formulation intended to replace EGRIFTA SV ® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy MONTREAL, Nov. 2 [Read more]